EP Patent

EP0483105B2 — Solid drug-delivery devices employing fatty acid esters or fatty alcohol ethers of alkanediols as percutaneous absorption enhancers

Assigned to Janssen Pharmaceuticals Inc · Expires 2001-01-17 · 25y expired

What this patent protects

A solid state, resilient laminated composite for administering estradiol transdermally consisting of a multiplicity of spaced structural laminas of a resilient elastomer, one of which forms the top of the composite, a viscoelastic hydrophobic polymer lamina containing propylene g…

USPTO Abstract

A solid state, resilient laminated composite for administering estradiol transdermally consisting of a multiplicity of spaced structural laminas of a resilient elastomer, one of which forms the top of the composite, a viscoelastic hydrophobic polymer lamina containing propylene glycol monolaurate interposed between each structural lamina and a pressure-sensitive adhesive lamina that provides the basal surface of the composite and consists of a blend of a pressure-sensitive adhesive, estradiol, and propylene glycol monolaurate. <IMAGE>

Drugs covered by this patent

Patent Metadata

Patent number
EP0483105B2
Jurisdiction
EP
Classification
—
Expires
2001-01-17
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.